ProCE Banner Activity

New Directions with PARP Inhibitors in Pancreatic Cancer: Podcast Pearls

PDF
In this downloadable PDF summary from a CCO podcast, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, compare the role and use of PARP inhibitors in the treatment of pancreatic cancer between the United States and Europe.

Released: May 03, 2022

Expiration: May 02, 2023

No longer available for credit.

Share

Faculty

Eileen O Reilly

Eileen O Reilly, MD

Associate Professor
Memorial Sloan Kettering Cancer Center
New York, New York

Naureen Starling

Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP

Associate Director of Clinical Research
Reader
Department of GI Cancers
The Royal Marsden Hospital/ICR
Consultant Medical Oncologist, GI Cancers
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Eileen O Reilly, MD

Associate Professor
Memorial Sloan Kettering Cancer Center
New York, New York

Eileen M. O’Reilly, MD, has disclosed that she has received funds for research support from Agios, Arcus, AstraZeneca, BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Silenseed, and Yiviva and consulting fees from Adicet, Alnylam, AstraZeneca, Autem, Bayer, BeiGene, Berry Genomics, Celgene, Cend, CytomX, Eisai, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Lilly, Merck, Nerviano, QED, Rafael, Redhill, Servier, Silenseed, Sobi, Surface Oncology, Therabionics, Vector, and Yiviva.

Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP

Associate Director of Clinical Research
Reader
Department of GI Cancers
The Royal Marsden Hospital/ICR
Consultant Medical Oncologist, GI Cancers
London, United Kingdom

Naureen Starling, MD, FRCP, has disclosed that she has received consulting fees from Amgen, GSK, Lilly, MSD, Novartis, Pierre Fabre, and Servier.